Welcome to Markets Desk, here's what's moving right now.
Eli Lilly's dominance in the GLP-one space is becoming almost impossible to ignore. The company is now valued at nearly nine times that of Novo Nordisk, a stunning reversal given that Novo entered the market first. The gap reflects investor conviction that Lilly's pipeline and execution have simply outpaced its Danish rival by a wide margin.
Shifting to aerospace, Boeing's contract losses are coming into sharper focus, and the picture isn't encouraging. Defense and commercial programs alike are bleeding red ink, with fixed-price contracts proving particularly punishing. Investors are watching closely to see whether management can stabilize margins or whether the write-downs have further to run heading into year-end.
And in Washington, Secretary of State Marco Rubio offered a sobering assessment of nuclear talks with Iran, calling Tehran's demands outrageous and signaling little hope for a near-term diplomatic breakthrough. Markets sensitive to Middle East risk, particularly energy, will be watching any escalation carefully, as a breakdown in negotiations carries real implications for oil supply stability.
That's the tape. Markets Desk, signing off the floor.
